A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
- Conditions
- unresectable or recurrent gastric cance
- Registration Number
- JPRN-UMIN000016196
- Lead Sponsor
- Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 37
Not provided
1. Patients with serious drug allergy 2. Patients with history of receiving paclitaxel treatment 3. Patients with infectious disease and febrile condition (over 38 centigrade) 4. Patiens with any other serious disease. 5. Patients with severe diarrhea 6. Patients with fresh bleeding from intestinal tract. 7. Patients with serious heart disease 8. Presence of active multiple primaries. (Active multiple primaries is simultaneous or metachronous with disease-free interval of 5 years or more. But, carcinoma in situ and skin cancer which are judged to be recovery by medical treatment are excluded.) 9. Patients with peripheral neuropathy(=>Grade2) 10. Patients wit psychological illness 11. Pregnant or nursing female 12. Patient with brain metastasis. 13. Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method